Dr. Heidi Overton

Role status — October 2026: Overton is President Trump’s nominee for FDA Commissioner, nominated in August 2026 after Marty Makary’s May resignation. Kyle Diamantas leads the agency in an acting capacity meanwhile. Her Senate HELP Committee confirmation hearing was held September 24, 2026; the committee vote has been pushed past the midterm elections.

Heidi Overton, MD, PhD, serves as a deputy assistant to the president for domestic policy. Before her White House role she was a surgical oncologist associated with Johns Hopkins.

Her nomination has drawn scrutiny over her role in a White House executive order that reduced the number of recommended childhood vaccines — a role HELP Chairman Bill Cassidy reportedly called “almost disqualifying” (Punchbowl News, via Medical Daily). Cassidy said the day before her hearing that he was “trying to be neutral in my preconception”; Sen. Lisa Murkowski described Overton as “well rehearsed in her responses” and remained undecided. At the hearing, Overton told senators she would “follow statutory guidelines” and “review the evidence” on pending questions including mifepristone rules and vaccine review policy, without committing to specific outcomes (attributed to her testimony as reported).

Why she matters to this chronicle: the FDA has lacked a confirmed commissioner since May 2026, and major shifts tend to wait for permanent leadership. Overton’s confirmation — or its failure — will shape the agency’s direction on vaccine policy, drug approvals, and the food program through the rest of the MAHA era.

Sources (Oct 2026): Medical Daily on the delayed committee vote and hearing; Becker’s Hospital Review on the Sept. 24–25 nomination actions; Nutritional Outlook and Vitamin Retailer on the Makary resignation and Diamantas acting role.